Trial Profile

A Phase 1 First in Human Study of ARV-393 in Adult Participants With Advanced Non-Hodgkin's Lymphoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ARV 393 (Primary)
Indications B-cell lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
Focus Adverse reactions; First in man
Sponsors Arvinas

Most Recent Events

01 May 2025 According to an Arvinas media release, company to share preliminary clinical data in 2H 2025.
11 Feb 2025 According to an Arvinas, Inc. media release, company continued recruiting patients in this trial.
10 Jan 2025 According to an Arvinas media release, the company plans to share initial data from this study in 1H 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com